PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8255759-2	1993	Treatment of cells with tumour necrosis factor (TNF), double-stranded RNA (dsRNA), or phorbol esters is shown to be associated with an increase in the rate of p105 to p50 processing, and the loss of immunologically detectable MAD3/I kappa B alpha.	Phorbol Esters	86-100	nuclear factor kappa B subunit 1	Homo sapiens	159-163	
8255759-2	1993	Treatment of cells with tumour necrosis factor (TNF), double-stranded RNA (dsRNA), or phorbol esters is shown to be associated with an increase in the rate of p105 to p50 processing, and the loss of immunologically detectable MAD3/I kappa B alpha.	Phorbol Esters	86-100	nuclear factor kappa B subunit 1	Homo sapiens	167-170	
8255759-2	1993	Treatment of cells with tumour necrosis factor (TNF), double-stranded RNA (dsRNA), or phorbol esters is shown to be associated with an increase in the rate of p105 to p50 processing, and the loss of immunologically detectable MAD3/I kappa B alpha.	Phorbol Esters	86-100	NFKB inhibitor alpha	Homo sapiens	226-230	
8255759-2	1993	Treatment of cells with tumour necrosis factor (TNF), double-stranded RNA (dsRNA), or phorbol esters is shown to be associated with an increase in the rate of p105 to p50 processing, and the loss of immunologically detectable MAD3/I kappa B alpha.	Phorbol Esters	86-100	NFKB inhibitor alpha	Homo sapiens	231-246	
8255759-3	1993	Phosphate-labelling experiments indicate that these events are preceded by the phosphorylation of MAD3 and p105.	Phosphates	0-9	NFKB inhibitor alpha	Homo sapiens	98-102	
8255759-3	1993	Phosphate-labelling experiments indicate that these events are preceded by the phosphorylation of MAD3 and p105.	Phosphates	0-9	nuclear factor kappa B subunit 1	Homo sapiens	107-111	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-lysine chloromethyl ketone	30-74	nuclear factor kappa B subunit 1	Homo sapiens	152-156	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-lysine chloromethyl ketone	30-74	nuclear factor kappa B subunit 1	Homo sapiens	160-163	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-lysine chloromethyl ketone	30-74	NFKB inhibitor alpha	Homo sapiens	179-183	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-lysine chloromethyl ketone	30-74	nuclear factor kappa B subunit 1	Homo sapiens	232-242	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-phenylalanine chloromethyl ketone	86-137	nuclear factor kappa B subunit 1	Homo sapiens	152-156	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-phenylalanine chloromethyl ketone	86-137	nuclear factor kappa B subunit 1	Homo sapiens	160-163	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-phenylalanine chloromethyl ketone	86-137	NFKB inhibitor alpha	Homo sapiens	179-183	
8255759-4	1993	The protease inhibitors TLCK (N alpha-p-Tosyl-L-Lysine Chloromethyl Ketone) and TPCK (N alpha-p-Tosyl-L-Phenylalanine Chloromethyl Ketone) inhibit both p105 to p50 processing and MAD3 degradation, and also cause a complete block to NF-kappa B activation.	n alpha-p-tosyl-l-phenylalanine chloromethyl ketone	86-137	nuclear factor kappa B subunit 1	Homo sapiens	232-242